USPTO serial 79382427
ZORYA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 25, 2025
- Examiner
- REID, CAILE MAUREEN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ZORYA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Steven J. Solomon
Steven J. Solomon Tucker Ellis LLP950 Main Avenue, Suite 1100Cleveland, OH 44113United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; veterinary products, namely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; sanitary preparations for medical use; chemical and biological preparations for medical use, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases, and biological preparations for pharmaceutical use being biological preparations for use in cell cultures for medical purposes | ACTIVE | — |
| 009 | Quality control and testing devices namely culture plates to test and conduct quality control in the field of biology, biotechnology and pharmacy; downloadable software for the collection, processing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instruments, namely computer hardware and downloadable software for data analysis, database management, data processing, in the field of life science research and the pharmaceutical industry market and diagnostics | ACTIVE | — |
| 042 | Medical, biotechnological, and pharmaceutical research; research and development of chemical, biological and scientific products and materials in the biological, biotechnological, medical, diagnostic and pharmaceutical fields; scientific research, advisory and information services in the medical, biotechnological, pharmaceutical, diagnostic, technological and industrial fields; design and development of computers, software and computer platforms; technical testing namely technological testing in the scientific, biological, biotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testing, technical testing namely, technological testing in the scientific, biological, biotechnological and medical fields, and scientific research advisory services with respect to scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imaging, in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; diagnostic and industrial research in the biological, biotechnological and medical fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 3, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 11, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 11, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 25, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 19, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 31, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 31, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 25, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 25, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 7, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 7, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 1, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 22, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 22, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 22, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 22, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 22, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 23, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 16, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 25, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 25, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 2, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 1, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 20, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 7, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 3, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 2, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |